SLS BIO Co., Ltd (KOSDAQ:246250)
South Korea
· Delayed Price · Currency is KRW 1,969.00
+85.00 (4.51%)
At close: Jun 9, 2025
SLS BIO Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2015 | 2014 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '15 Dec 31, 2015 | 2014 |
| Operating Revenue | 3,984 | 8,371 | 9,023 | 10,752 | 6,214 | Upgrade
|
| Other Revenue | 0 | - | - | -0 | 0 | Upgrade
|
| Revenue | 3,984 | 8,371 | 9,023 | 10,752 | 6,214 | Upgrade
|
| Revenue Growth (YoY) | -52.41% | -7.23% | -16.08% | 73.02% | 6.75% | Upgrade
|
| Cost of Revenue | 5,921 | 6,102 | 5,912 | 6,542 | 4,851 | Upgrade
|
| Gross Profit | -1,937 | 2,269 | 3,111 | 4,210 | 1,363 | Upgrade
|
| Selling, General & Admin | 1,450 | 1,195 | 1,294 | 1,119 | 416.94 | Upgrade
|
| Research & Development | 596.11 | 591 | 533.56 | 503.7 | 303.66 | Upgrade
|
| Amortization of Goodwill & Intangibles | 24.26 | 24.04 | 20.08 | 17.53 | 20.64 | Upgrade
|
| Operating Expenses | 2,168 | 1,981 | 2,080 | 1,786 | 840.46 | Upgrade
|
| Operating Income | -4,105 | 287.62 | 1,031 | 2,424 | 522.53 | Upgrade
|
| Interest Expense | -66.57 | -83.92 | -100.85 | -135.99 | -336.36 | Upgrade
|
| Interest & Investment Income | 174.72 | 282.53 | 166.85 | 122.76 | 9.12 | Upgrade
|
| Currency Exchange Gain (Loss) | -0.24 | -1.87 | -0.21 | -0.07 | - | Upgrade
|
| Other Non Operating Income (Expenses) | -1,382 | -130.24 | -0.38 | 10.51 | -1.52 | Upgrade
|
| EBT Excluding Unusual Items | -5,380 | 354.11 | 1,096 | 2,421 | 193.76 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | -39.06 | -236.35 | - | Upgrade
|
| Gain (Loss) on Sale of Assets | 0.14 | -0 | -0.01 | 40.3 | 4 | Upgrade
|
| Pretax Income | -5,380 | 354.11 | 1,057 | 2,225 | 197.76 | Upgrade
|
| Income Tax Expense | -475.94 | 18.49 | -376.67 | -601.13 | -6.71 | Upgrade
|
| Net Income | -4,904 | 335.63 | 1,434 | 2,826 | 204.47 | Upgrade
|
| Net Income to Common | -4,904 | 335.63 | 1,434 | 2,826 | 204.47 | Upgrade
|
| Net Income Growth | - | -76.60% | -49.26% | 1282.14% | -36.46% | Upgrade
|
| Shares Outstanding (Basic) | 15 | 15 | 7 | 7 | 5 | Upgrade
|
| Shares Outstanding (Diluted) | 15 | 15 | 7 | 7 | 5 | Upgrade
|
| Shares Change (YoY) | -1.40% | 116.87% | 2.55% | 37.54% | 14.68% | Upgrade
|
| EPS (Basic) | -326.00 | 22.00 | 203.87 | 412.00 | 41.00 | Upgrade
|
| EPS (Diluted) | -326.00 | 22.00 | 203.86 | 412.00 | 41.00 | Upgrade
|
| EPS Growth | - | -89.21% | -50.52% | 904.88% | -44.59% | Upgrade
|
| Free Cash Flow | -3,709 | 269.92 | 2,162 | 3,315 | 97.66 | Upgrade
|
| Free Cash Flow Per Share | -246.54 | 17.69 | 307.30 | 483.26 | 19.58 | Upgrade
|
| Gross Margin | -48.63% | 27.10% | 34.48% | 39.16% | 21.93% | Upgrade
|
| Operating Margin | -103.05% | 3.44% | 11.43% | 22.54% | 8.41% | Upgrade
|
| Profit Margin | -123.09% | 4.01% | 15.89% | 26.28% | 3.29% | Upgrade
|
| Free Cash Flow Margin | -93.09% | 3.22% | 23.96% | 30.83% | 1.57% | Upgrade
|
| EBITDA | -2,822 | 1,624 | 2,309 | 3,727 | 1,139 | Upgrade
|
| EBITDA Margin | -70.84% | 19.40% | 25.59% | 34.66% | 18.32% | Upgrade
|
| D&A For EBITDA | 1,283 | 1,336 | 1,278 | 1,303 | 616.03 | Upgrade
|
| EBIT | -4,105 | 287.62 | 1,031 | 2,424 | 522.53 | Upgrade
|
| EBIT Margin | -103.05% | 3.44% | 11.43% | 22.54% | 8.41% | Upgrade
|
| Effective Tax Rate | - | 5.22% | - | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.